β2-微球蛋白(β2-microglobulin,β2M)淀粉样变,又称透析相关性淀粉样变(dialysis related amyloi-dosis,DRA),是长期血液透析患者常见而严重的致残性并发症,主要表现为发生在关节和关节周围骨组织的淀粉样物沉积。1985年由Gejvo等人首次提出透析相关性淀粉样变(DRA),随后发现在透析前及其它非移植性肾脏替代治疗等情况下也可发生,因淀粉样物质的主要成分是β2-微球蛋白,故目前 β2-microglobulin (β2M) Amyloidosis, also known as dialysis-related amyloi-dosis (DRA), is a common and serious disabling complication of long-term hemodialysis patients, mainly Amyloid deposits occur in the joints and surrounding bony tissue. Dialysis-related amyloidosis (DRA) was first proposed by Gejvo et al. In 1985 and subsequently found to occur even before dialysis and other non-transplant renal replacements because the major component of amyloid is β2-microspheres Protein, so at the moment